top of page
28 juil. 2022
Spexis extended its cash runway into January 2023, refocused resources on its Phase 3 ColiFin® program, and renewed a CHF 15 million equity-linked financing with IRIS.
ALLSCHWIL, Switzerland, July 28, 2022 – Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today provides a business update, including development programs’ progress and its efforts to secure funding for these projects.
Download Spexis press release
bottom of page